Obesity causes dysfunction of adipose tissue, with resultant chronic inflammation and 27 adverse interplay of various adipokines, sex steroids and endocrine hormones. All 28 these drive tumourigenesis and explain the epidemiological link between obesity and 29 cancer. Over the past decade, the associations among obesity, adipokines and cancer 30 have been increasingly recognized. Adipokines and their respective signaling 31 pathways have drawn much research attention in the field of oncology and cancer 32 therapeutics. This review will discuss the recent advances in the understanding of the 33 association of several adipokines with common obesity-related cancers, and the 34 clinical therapeutic implications. Tackling obesity is a growing challenge. The increasing prevalence of obesity 53 worldwide does not just propel the upsurge of incident diabetes, metabolic syndrome 54 and cardiovascular diseases, but also of incident cancers. A meta-analysis, involving 55 282137 incident cases from prospective observational studies, had shown that 56 increased body mass index (BMI) was associated with a higher risk of both common 57 and less common cancers. (1) Increased risks of incident cancers by 6 to 59%, 58 involving oesophageal adenocarcinoma, leukaemia, non-Hodgkin lymphoma, colon, 59 thyroid and renal cancers, were associated with every increment of 5 kg/m 2 in BMI 60 above normal in both sexes. In men, significant positive associations were also noted 61
with rectal cancer and malignant melanoma. In women, positive associations were 62 found with endometrial, gallbladder, pancreatic and post-menopausal breast cancers 63 as well. (1) In fact, Calle et al had estimated that in the United States, obesity 64
contributed to 14% of all cancer mortality in men and 20% of those in women. (2) In 65 UK, a recent population-based cohort study involving 166955 subjects with cancer, 66
suggested that BMI was associated with 17 out of 22 cancers studied. Furthermore, it 67 also estimated that every unit of population-wide increment in BMI would lead to an 68 addition of 3790 UK subjects developing one of the ten common obesity-related 69 cancers annually. (3) In Asian-Pacific populations, a meta-analysis also showed that 70 every increment of 5 units in BMI above 18.5 kg/m 2 was associated with an increase 71 in cancer mortality by 1.09 for all cancers. (4) In Chinese, although the overall 72 prevalence of obesity is lower than the west, even when Asian-Pacific BMI cut-offs 73 are used (5) , obesity has also been demonstrated as an independent predictor of 74 incident cancers. In a community-based cohort of 2895 Hong Kong Chinese subjects 75 indicator of central adiposity, independently predicted incident cancers with a 78 standardized odds ratio of 1.19 (95% CI 1.02 -1.40; p = 0.031) even after adjustment 79 for age of subjects. (6) All these suggested that the association between obesity and 80 cancer was consistent across populations worldwide. In fact, in Asian-Pacific 81 populations, the association between increased BMI and breast cancer was even 82 stronger, in both pre-and post-menopausal women, than in populations of North 83 America, Europe and Australia. (1) Recent meta-analyses also suggested that both 84 pre-and post-menopausal breast cancer patients who were obese had poorer overall 85 survival regardless of when BMI was ascertained. (7) 0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7  8  9  0  1  2  3  4  5  6  7 To date, more than 15 adipokines have been reported in the literature to be associated 125 with cancers and this list is still growing. (11, 13) While the circulating levels of 126 majority of pro-inflammatory adipokine levels, like leptin (Table 1) , IL-6 and tumour 127 necrosis factor alpha (TNF-α), are increased in cancers, some adipokines like 128 adiponectin are protective against tumourigenesis and its serum levels are usually 129 decreased in the cancer patients. (11) (Table 1) We previously demonstrated that, in a 130
Chinese community cohort in Hong Kong, subjects who developed cancers also had 131 higher baseline levels of C-reactive protein, IL-6, soluble tumour necrosis factor 132 receptor 2 (a surrogate marker of TNF-α activity) and lipocalin 2. (6) 133 134
New insights into the role of specific adipokine in various obesity-related cancers 135 136
Adiponectin 137
Adiponectin is one of the most abundant adipokines secreted by adipocytes. It is 138 secreted into the circulation as three oligomeric complexes, including trimer, 139 hexamer, and high molecular weight (HMW) multimer. Among them, HMW 140 adiponectin is the major active form mediating the insulin sensitizing effect of this 141 adipokine. (14) Adiponectin has been shown to modulate the biological actions of 142 several growth factors, including platelet-derived growth factor BB, basic fibroblast 143 growth factor, and heparin-binding epidermal growth factor-like growth factor, 144 through specific binding of these growth factors in an oligomerization dependent 145 manner, with HMW adiponectin being able to bind all three growth factors. (15) 146 These in vitro findings suggest that adiponectin, especially HMW adiponectin, can 147 exert its anti-proliferative action by reducing the bioavailability of these growth 148 factors at a pre-receptor level. The biosynthesis and secretion of these oligomers by 149 act as a stromal factor that helps balance the local redox and metabolism. ( Hypoadiponectaemia increased the risk of Barrett's esophagus, which is more 223 prevalent in obese individuals and is closely associated with the development of 224 Inverse association between adiponectin and endometrial cancer, which remained 262 significant even after adjustment for estradiol levels and BMI, was only observed in 263 women not on menopausal hormonal therapy, suggesting that adiponectin might 264 influence cancer risk through mechanisms other than estrogen-mediated endometrial 265 proliferation. (38) In fact, adiponectin might exert its anti-cancer effect via the NF-κB 266 signaling pathway to suppress vascular endothelial growth factor (VEGF) expression. 267 (27) Furthermore, in vitro studies also showed its suppression of endometrial cancer 268 cell proliferation via enhancing the expression of the adaptor molecule LKB1, which 269 is required for adiponectin-involved activation of AMPK. (39) findings, it has also been suggested that adiponectin might be employed as a 277 biomarker for renal cell cancer progression, as both total and high molecular weight 278 oligomers were demonstrated to be higher in patients with localized disease than those 279 with metastatic clear cell carcinoma, the commonest subtype of renal cell carcinoma. 280 On the contrary, although studies on the association between leptin and pancreatic 370 cancer are scarce, most of them showed that leptin levels were lower in patients with 371 pancreatic cancer than in controls. While some had attributed the hypoleptinaemia to 372 the weight loss that was commonly observed in pancreatic cancer patients (27) significantly lower serum leptin levels and these differences were independent of age 375 and BMI. (56) In vitro studies also showed that leptin could inhibit human pancreatic 376 cancer cell lines PANC-1 and Mia-PaCa. (27) 
IL-6, TNF-α α α α and various cancers 410
Both IL-6 and TNF-α are key cytokines involved in inflammation and immunity. 411
They are produced and secreted by several cells, including macrophages and 412 adipocytes. Both M1 and M2 macrophages are present in adipose tissue, but they 413 differ in the profile of cytokines they produced. In the context of obesity, local tissue 414 hypoxia around adipocytes promotes the switch of macrophages from M2 to the M1 415 phenotype. This changes the production profile from anti-inflammatory cytokines like 416 interleukin-10 of the M2 macrophages to pro-inflammatory cytokines like IL-6 and 417 TNF-α of the M1 macrophages. (9) Consequently, both the production and secretion 418 of these two adipokines are increased, and together they enhance tumourigenesis via 419 their pro-inflammatory effects. IL-6 promotes carcinogenesis mainly through the 420 JAK/STAT3 signaling pathway, which is involved in tumour proliferation, survival 421 and angiogenesis. TNF-α, on the other hand, activates the NF-κB and JNK signaling 422 
Other adipokines and cancers 453
Increasing epidemiological evidence has shown that a number of other adipokines are 454 also involved in obesity-related cancers. Neutrophil gelatinase-associated lipocalin 455 (NGAL) or lipocalin-2, for example, was over-expressed in breast, gastric, esophagus 456 and brain cancers. (11) Recently, lipocalin-2 was also noted to be associated with 457 tumour invasiveness, possibly attributed to its ability to scavenge iron into cancer 458 cells. (64) Resistin, another pro-inflammatory adipokine, was found to be present at 459 higher levels in advanced non-small cell lung, colon, breast and prostate cancers. (11) 460
A recent meta-analysis also suggested a consistent positive association between 461 resistin and colorectal cancers, although the number of studies was limited. (37) 462 463
Clinical and therapeutic implications 464
Owing to the fast growing prevalence of both obesity and cancer worldwide, together 465 with their associated morbidity and mortality, they have become major global 466 Although there are emerging data on the association between genetic polymorphisms 505 of obesity-related genes and cancer susceptibility, there is currently insufficient 506 evidence to recommend their use as predictors for incident cancer, or as prognostic 507 biomarkers in those who have developed cancer. Nevertheless, a recent meta-analysis 508 suggested that the LEP G2548A polymorphism, which had been reported to alter 509 serum leptin levels, was associated with increased overall cancer risk (Odds ratio 510 1.27; 95% CI 1.05 -1.54). (68) However, with regard to adiponectin, no consistent 511 association has been found between cancer susceptibility and genetic polymorphisms 512 of either the adiponectin gene (ADIPOQ) or adiponectin receptor genes 513 (ADIPOR1/R2) in studies on non-Hodgkin's lymphoma, breast, colorectal and 514 prostate cancers. Three ADIPOQ single nucleotide polymorphisms (SNPs) had been 515 reported to be associated with a reduced risk of endometrial cancer in a Chinese 516 study. However, serum adiponectin level was not measured in that study and whether 517 these SNPs were biologically relevant remained to be elucidated. (16) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 47 48 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 47 48 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 
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